DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of March 30, 2026, DNTH stock price declined to $79.12 with 529,176 million shares trading.

DNTH has a beta of 1.12, meaning it tends to be more sensitive to market movements. DNTH has a correlation of 0.08 to the broad based SPY ETF.

DNTH has a market cap of $4.19 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $284,000 in Revenue and -$1.43 earnings per share. This fell short of revenue expectation by $-192,950 and missed earnings estimates by -$.42.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): IWM, VTI, XBI, IWN, VXF.

DNTH has outperformed the market in the last year with a price return of +298.2% while the SPY ETF gained +12.4%. DNTH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +89.1% and +1.6%, respectively, while the SPY returned -8.5% and -4.6%, respectively.

DNTH support price is $77.87 and resistance is $84.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.